3429 related articles for article (PubMed ID: 7357517)
1. Lymphokine-mediated immunotherapy studies in mouse tumor systems.
Papermaster BW; Gilliland CD; McEntire JE; Smith ME; Buchok SJ
Cancer; 1980 Mar; 45(5 Suppl):1248-53. PubMed ID: 7357517
[TBL] [Abstract][Full Text] [Related]
2. Lymphokine preparations: a new approach to cancer immunotherapy.
Papermaster BW; Kaltenbach ML
Mo Med; 1978 Dec; 75(12):607-9, 612. PubMed ID: 723839
[No Abstract] [Full Text] [Related]
3. Discussion paper: effect of supernatants from long-term lymphoid cell lines on metastatic cutaneous tumors following local injection.
Papermaster BW; Holtermann OA; McDaniel MC; Klein E; Djerassi I; Rosner D; Dao T; Costanzi JJ
Ann N Y Acad Sci; 1976; 276():584-91. PubMed ID: 68700
[TBL] [Abstract][Full Text] [Related]
4. Effect of lymphokine-containing sera on adenocarcinoma BW10232 and melanoma B16 in C57BL/6 mice.
Moulton RG; Daniels JC
J Natl Cancer Inst; 1980 Apr; 64(4):901-3. PubMed ID: 6154164
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy of murine and human tumors in mice with lymphokines and interleukin-2-propagated lymphocytes.
Kedar E; Chriqui-Zeira E; Kyriazis AP
J Biol Response Mod; 1984 Oct; 3(5):517-26. PubMed ID: 6334139
[TBL] [Abstract][Full Text] [Related]
6. A new mouse model of experimental melanoma for vaccine and lymphokine therapy.
Shrayer DP; Bogaars H; Wolf SF; Hearing VJ; Wanebo HJ
Int J Oncol; 1998 Aug; 13(2):361-74. PubMed ID: 9664134
[TBL] [Abstract][Full Text] [Related]
7. Tumor regression induced in mice by partially purified lymphokine fractions.
Papermaster BW; Gilliland CD; Smith M; Buchok S; McEntire JE; Butler RC; Specter S; Friedman H
Ann N Y Acad Sci; 1979; 332():451-9. PubMed ID: 316983
[No Abstract] [Full Text] [Related]
8. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
Papa MZ; Mulé JJ; Rosenberg SA
Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
[TBL] [Abstract][Full Text] [Related]
9. Treatment of experimental visceral leishmaniasis with lymphokine encapsulated in liposomes.
Reed SG; Barral-Netto M; Inverso JA
J Immunol; 1984 Jun; 132(6):3116-9. PubMed ID: 6725947
[TBL] [Abstract][Full Text] [Related]
10. Comparative effect of anaerobic coryneforms on a murine melanoma.
Paslin DA
Cancer; 1977 Jun; 39(6):2405-10. PubMed ID: 872039
[TBL] [Abstract][Full Text] [Related]
11. Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models.
Winkelhake JL; Stampfl S; Zimmerman RJ
Cancer Res; 1987 Aug; 47(15):3948-53. PubMed ID: 3496953
[TBL] [Abstract][Full Text] [Related]
12. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
[TBL] [Abstract][Full Text] [Related]
13. Therapy of spontaneous metastases by intravenous injection of liposomes containing lymphokines.
Fidler IJ
Science; 1980 Jun; 208(4451):1469-71. PubMed ID: 7384789
[TBL] [Abstract][Full Text] [Related]
14. An experimental screening for "systemic adjuvants of immunity" applicable in cancer immunotherapy.
Mathé G; Kamel M; Dezfulian M; Halle-Pannenko O; Bourut C
Cancer Res; 1973 Sep; 33(9):1987-97. PubMed ID: 4146853
[No Abstract] [Full Text] [Related]
15. Are syngeneic mouse tumor models still valuable experimental models in the field of anti-cancer drug discovery?
Darro F; Decaestecker C; Gaussin JF; Mortier S; Van Ginckel R; Kiss R
Int J Oncol; 2005 Sep; 27(3):607-16. PubMed ID: 16077908
[TBL] [Abstract][Full Text] [Related]
16. Intravenous, intralesional and endolymphatic administration of lymphokines in human cancer.
Pulley MS; Nagendran V; Edwards JM; Dumonde DC
Lymphokine Res; 1986; 5 Suppl 1():S157-63. PubMed ID: 3784610
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of macromomycin B (NSC 170105) against murine leukemias, melanoma, and lung carcinoma.
Lippman MM; Laster WR; Abbott BJ; Venditti J; Baratta M
Cancer Res; 1975 Apr; 35(4):939-45. PubMed ID: 1116151
[TBL] [Abstract][Full Text] [Related]
18. In vivo antitumor effect of lymphokine-activated rodent polymorphonuclear leukocytes.
Fujii Y; Kimura S; Arai S; Sendo F
Cancer Res; 1987 Nov; 47(22):6000-5. PubMed ID: 3117360
[TBL] [Abstract][Full Text] [Related]
19. Prolonged remissions of lymphatic leukemia in DBA-2 mice induced with endogenously produced lactate dehydrogenase antibody.
Lakatos G; Strefling A; Joseph RR; McCann DS
Cancer Res; 1974 Jun; 34(6):1395-400. PubMed ID: 4207862
[No Abstract] [Full Text] [Related]
20. Retrovirus-mediated immunosuppression. I. FeLV-UV and specific FeLV proteins alter T lymphocyte behavior by inducing hyporesponsiveness to lymphokines.
Orosz CG; Zinn NE; Olsen RG; Mathes LE
J Immunol; 1985 May; 134(5):3396-403. PubMed ID: 2984289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
